Bayer AG

BAYN

DE000BAY0017

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

94,245

Sector

Pharmaceuticals

Calendar

05/03/2025 - Q4 2024 Earnings Release

More about the company

Income Statement and Estimates

income-statement-evolution-chart BAYER-AG

More financial data

Analysis / Opinion

Bayer AG: A balancing act

November 13, 2024 at 10:21 am

BAYER : 2025: another year without a catalyst?

November 13, 2024 at 11:14 am

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

20.00EUR

Average target price

28.00EUR

Spread / Average Target

+40.05%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Xetra Other stock markets 16:35:05 11/12/2024 GMT			5-day change	1st Jan Change
20.00 ^EUR	-1.42%		+3.82%	-40.54%

12-11	Confirmed: Moberg Pharma's MOB-015 did not meet primary endpoint in phase 3 study (update)	FW
12-11	Moberg Pharma, Bayer to Call Off Licensing Deal for Nail Fungus Treatment	MT

Confirmed: Moberg Pharma's MOB-015 did not meet primary endpoint in phase 3 study (update)	12-11	FW
Moberg Pharma, Bayer to Call Off Licensing Deal for Nail Fungus Treatment	12-11	MT
Bayer: new analyses on heart failure	12-10	CF
Investors cash in on some Dax favorites	12-10	DP
BAYER AG : UBS is Neutral	12-09	ZD
Bayer continues to recover - Glyphosate mistrial in the USA	12-09	DP
Bayer: new €5 billion credit line	12-06	CF
Bayer Secures New EUR5 Billion Revolving Credit Facility	12-06	MT
Bayer competitor Corteva wants to significantly expand its soybean business in Brazil	12-05	DP
BAYER AG : JP Morgan reaffirms its Neutral rating	12-03	ZD
ZBD Pharma Gets China Approval for Antibacterial Injection	12-03	MT
Bayer: to present its radiology products at RSNA	12-02	CF
Bayer: expanding its global network of incubators	11-29	CF
BAYER AG : DZ Bank reiterates its Buy rating	11-27	ZD
German consumer sentiment tumbles in December on job cut fears, GfK report shows	11-27	RE
BridgeBio Pharma Obtains FDA Approval of Attruby	11-25	MT
Dhanuka Agritech Limited Announces Strategic Acquisition Agreement with Bayer AG for Acquiring International Rights to the Active Ingredients Iprovalicarb and Triadimenol	11-25	CI
Dhanuka Agritech Limited Announces Strategic Acquisition Agreement with Bayer AG for Acquiring International Rights to the Active Ingredients Iprovalicarb and Triadimenol to Expand its Global Footprint	11-25	CI
Dhanuka Agritech to Acquire Crop Protection Active Ingredients from Germany's Bayer	11-25	MT
Dhanuka Agritech Limited signed an agreement to acquire international rights to the active ingredients Iprovalicarb and Triadimenol from Bayer Aktiengesellschaft.	11-24	CI
Hua Medicine Terminates Commercialization Agreement with Bayer for Type 2 Diabetes Treatment	11-22	MT
US FDA Accepts Bayer's Supplemental Application for Prostate Cancer Drug	11-21	MT
Bayer: new Nubeqa application filed in the USA	11-21	CF
Bayer at its lowest level in more than 20 years - investors run away	11-21	DP
BAYER AG : UBS sticks Neutral	11-21	ZD

Bayer AG

Equities